NCT05483348 is a clinical trial of Endometrial Ablation in Uterine Bleeding, sponsored by Naser Al-Husban.

Who is sponsoring NCT05483348?

NCT05483348 is sponsored by Naser Al-Husban.

What drugs are being tested in NCT05483348?

Interventions in NCT05483348: Endometrial Ablation, Repeated gynecological procedure.

What condition does NCT05483348 study?

NCT05483348 studies Uterine Bleeding, Treatment Failures, Prognostic Factors.

Is NCT05483348 still recruiting?

NCT05483348 is currently completed. Last updated 2 August 2022.

Last reviewed 2022-08-02 · How we verify

NCT05483348

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Predictive Factors of Success of Hysteroscopic Endometrial Ablation/Resection

Completed Last updated 2 August 2022

What this trial tests

trial testing Endometrial Ablation in Uterine Bleeding in 95 participants. Completed in 28 April 2022.

Timeline

17 February 2022

Primary endpoint
28 April 2022

28 April 2022

Quick facts

Lead sponsor	Naser Al-Husban
Status	Completed
Study type	OBSERVATIONAL
Enrollment	95
Start date	17 February 2022
Primary completion	28 April 2022
Estimated completion	28 April 2022
Sites	1 location across Jordan

Drugs / interventions tested

Endometrial Ablation
Repeated gynecological procedure

Conditions studied

Uterine Bleeding — all drugs for Uterine Bleeding →
Treatment Failures — all drugs for Treatment Failures →
Prognostic Factors — all drugs for Prognostic Factors →

Sponsor

Naser Al-Husban

Who can join

Eligibility, female only, with Uterine Bleeding or Treatment Failures. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the predictive factors of endometrial ablation failure in the management of uterine bleeding.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Uterine Bleeding

Currently open trials in the same condition.

NCT05224726 — Platelet Rich Plasma for Uterine Scar · NA · recruiting
NCT06953076 — Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn Study · recruiting
NCT06308172 — Impact of Single- Versus Double-layer Hysterotomy Closure on Cesarean Niche Development: a Randomized Controlled Trial · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05483348 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Naser Al-Husban
Last refreshed: 2 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05483348.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing